Hexarelin
Also known as: Examorelin, EP-23905
Overview
Hexarelin is a synthetic hexapeptide member of the GHRP family with potent GH-releasing activity. It is unique among GHRPs for its demonstrated direct cardiovascular effects that are independent of GH secretion. Hexarelin binds to CD36, a multifunctional scavenger receptor expressed in cardiomyocytes and microvascular endothelial cells, triggering dose-dependent coronary vasoconstriction and conferring cardioprotective effects against ischemia-reperfusion injury in GH-deficient and senescent animals.
Mechanism of Action
Hexarelin acts via two distinct mechanisms: (1) GHS-R1a receptor binding in pituitary and hypothalamus to drive GH secretion via PKC signaling; (2) direct binding to cardiac CD36 receptors, modulating coronary vascular tone and providing cardioprotection through L-type calcium channel involvement. The cardiac receptor is distinct from pituitary GHS-R1a, explaining the GH-independent cardiac effects. It also blocks SMC phenotype switching and NF-κB inflammatory signaling.
Potential Benefits
- Potent GH secretagogue comparable to GHRP-6
- GH release at both pituitary and hypothalamic levels
- Unique direct cardioprotective effects via CD36 activation
- Protection against postischemic ventricular dysfunction
- Stimulates IGF-1 in short-stature children
- Anti-inflammatory via NF-κB inhibition
- Potential cardiac remodeling benefits in heart failure
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg 2x daily |
| Intermediate | 150-200 mcg 2-3x daily |
| Advanced | 200 mcg 3x daily (not recommended past 6 weeks due to desensitization) |
| Cycle Duration | 4-6 weeks (tolerance develops beyond this) |
Strong GH releaser but prone to rapid tolerance. Inject on empty stomach, 20-30 min before meals or 1-2 hours after. Cortisol and prolactin elevation possible.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High systemic availability
Standard route. Inject into abdominal fat or thigh. Rotate sites.
Intranasal Lower but practical
Used in some clinical studies for diagnostic GH testing. Less common for research protocols.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Hexarelin:
Classic GH Pulse Stack
Amplifies natural GH pulse. Hexarelin 100 mcg + CJC-1295 No-DAC 100 mcg 2x daily on empty stomach for 4 weeks, then break.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2 mg, 5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Side Effects & Safety
- Cortisol and prolactin elevation
- Appetite stimulation
- Cardiac effects (coronary vasoconstriction) may limit therapeutic use
- Water retention
- Desensitization with chronic use
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Uncontrolled Diabetes Mellitus
Severe Cardiac Disease
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Insulin / Oral Hypoglycemics:
Pharmacokinetics
| Half-Life | ~55 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Hexarelin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.